Sponsored by
Novocure's Tumor Treating Fields (TTF) technology first earned FDA approval for recurrent glioblastoma in 2011 and for newly diagnosed glioblastoma in 2015 (Optune Gio). While some in the neuro-oncology community have been skeptical of TTF, the technology went on to gain FDA approval for malignant pleural mesothelioma in 2019 and for metastatic non-small cell lung cancer in 2024 (Optune Lua).
This past week, Novocure received FDA approval for TTF for locally advanced pancreatic cancer, used in combination with gemcitabine and nab-paclitaxel (Optune Pax).
While TTF by itself is not a cure for brain cancer, the steadily expanding list of FDA-approved indications reinforces that this technology has demonstrated meaningful clinical efficacy across multiple solid tumor types.